AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the ...

The Evolution Summit is designed to address the most pressing challenges and opportunities in clinical trials, with a focus ...